Fritextsökning
Innehållstyper
-
Decades of research destroyed at KI – a hacker attack cannot be ruled out!
Years of research, together with half a billion Swedish krona, went up in smoke when the freezers at Karolinska Institutet overheated. The breakdown has now bee...
-
Optimize Courier SUPPLIERS (DISTRIBUTORS)
-
Webinar: Support Trial Patients Transitioning to the Commercial Space
Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.
-
CTC Clinical Trial Consultants AB
-
How to transport hydrogen - the BionicHydrogenBattery
Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.
-
Danish biotech to buy struggling American oncology company
Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
One last chance to register for the premier metrology event in 2024
ZEISS QUALITY INNOVATION SUMMIT.
-
The first Lyme disease vaccine faces a delay
Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the ...
-
Tio life science-projekt får miljonanslag – ny utlysning öppnar
En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Chalmersforskare: Bättre riskbedömning med lipoprotein än kolesterol
I stället för att mäta kolesterolvärdet i blodet för att förutse risken för hjärtinfarkt kan ett enkelt test av lipoproteinmarkörer ge bättre information. Det h...
-
New Horizons in Biologics & Bioprocessing: Copenhagen 2026
-
SupraCube - In life Science
Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...
-
KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”
Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previou...
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
USA lämnar Världshälsoorganisationen
USA:s nyinstallerade president Donald Trump har lagt en presidentorder på att USA ska lämna Världshälsoorganisationen, WHO.
-
Johan Pehrson takes over the responsibility for research policy in Sweden
The Liberals' party leader Johan Pehrson takes over the assignment as Minister for Education. This was announced by Prime Minister Ulf Kristersson (M) on Tuesday last week.
-
AstraZeneca to use American AI platform for cancer trials
In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.